CN113226277B

CN113226277B - Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation

Info

Publication number: CN113226277B
Application number: CN201980086762.9A
Authority: CN
Inventors: 小寺启贵; 仁木洋子; 小山美穗; 胜间田祐贵; 桥本明宏; 远藤香凛; 上田刚士; 大桥幸浩
Original assignee: Nippon Fine Chemical Co Ltd
Current assignee: Nippon Fine Chemical Co Ltd
Priority date: 2018-12-26
Filing date: 2019-09-10
Publication date: 2023-12-01
Anticipated expiration: 2039-09-10
Also published as: KR20210107772A; WO2020137017A1; CN113226277A

Abstract

The invention provides a new application of phosphatidylinositol. And provides a composition capable of simply and stably dispersing phosphatidylinositol in water and a technique for simply and stably dispersing phosphatidylinositol in water. Phosphatidylinositol (PI), in particular, a high-concentration PI composition produced by a specific method can be used as a whitening agent, a hyaluronic acid production promoter, a collagen production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent, and a wrinkle-improving agent. The technical problem of the present invention can be solved by removing the organic solvent from a solution in which the component (A1) phosphatidylinositol, the component (A2) lecithin and the component (A3) sterols are uniformly dissolved in the organic solvent to obtain a complex in which the components (A1) to (A3) are simultaneously precipitated, and a cosmetic or skin external preparation containing the component (a) composition containing phosphatidylinositol and lecithin, the component (B) polyol and the component (C) water as essential components.

Description

Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation

Technical Field

The present invention relates to a phosphatidylinositol-containing whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-reducing agent, wrinkle-improving agent, complex, cosmetic, and external preparation for skin.

Background

Lecithin is a generic term for glycerophospholipids obtained from animals or plants, and is widely used as a natural emulsifier in foods, cosmetics, pharmaceuticals, and the like. The constituent components of lecithin are classified according to the structure of a polar group bonded to a phosphate group, and phosphatidylcholine (hereinafter, also simply referred to as PC.), phosphatidylethanolamine (hereinafter, also simply referred to as PE.), phosphatidylserine (hereinafter, also simply referred to as PS.), phosphatidylinositol (hereinafter, also simply referred to as PI.), phosphatidic acid (hereinafter, also simply referred to as PA.), and the like are known as main components. In recent years, studies have been made focusing on various functions and effects of these, and among them, PI is known to be closely related to an intracellular and extracellular information transfer function, and physiological actions of reducing triglyceride concentration in blood and increasing HDL cholesterol by taking PI have been reported. In addition, physiological actions such as an increase in hyaluronic acid of skin (patent document 1) and an increase in Nrf2 activity (patent document 2) have also been reported, but the physiological actions of PI have not been sufficiently studied yet.

When PI is used as an active ingredient for various applications, it is important to obtain a composition containing PI at a high concentration, and as a method for this, a method of separating fractionated lecithin by solvent separation (for example, patent document 3) and column purification has been conventionally used, but there are problems in terms of complicated production and cost. Meanwhile, recently, a method for efficiently producing PI using a phospholipase having substrate specificity that does not substantially act on PI but specifically acts on phospholipids other than PI has been developed (patent documents 4 and 5). According to this method, a composition containing PI at a high concentration can be industrially obtained at low cost. Patent document 4 describes that a composition containing PI at a high concentration obtained by the method can be used in foods, pharmaceuticals or cosmetics, but the function thereof has not been sufficiently studied, and it has been limited to food use at the present stage.

In general, although a method of using a polyoxyethylene surfactant or the like in combination is known as a method of solving such a problem, for example, in which PI has a poor emulsifying power as compared with other phospholipids (patent document 6), there is a concern about safety and skin irritation of a synthetic surfactant, and a method of not using or reducing the synthetic surfactant is desired. Patent document 7 discloses a lecithin-sterol complex obtained by removing an organic solvent from a solution in which lecithin and sterol are uniformly dissolved in the organic solvent, and precipitating both lecithin and sterol, as a method of dispersing lecithin lacking hydration in water. Patent document 8 discloses a water-insoluble physiologically active substance-phospholipid complex obtained by removing an organic solvent from a solution in which a physiologically active substance and a phospholipid which are insoluble in water are uniformly dissolved in the organic solvent and precipitating the physiologically active substance and the phospholipid at the same time, and the use of the complex can easily emulsify and solubilize the physiologically active substance which is insoluble in water, and the obtained composition has good dispersion stability. However, a complex containing phosphatidylinositol, lecithin and sterols at a specific ratio is not known.

As a technique for dispersing phospholipids in water, a method using a polyol is known (for example, patent documents 9 and 10). However, no technology for dispersing phosphatidylinositol using a polyol is known.

Prior art literature

Patent literature

Patent document 1: international publication No. 2009/110205

Patent document 2: japanese patent application laid-open No. 2011-168641

Patent document 3: japanese patent laid-open No. 60-246305

Patent document 4: international publication No. 2007/010892

Patent document 5: japanese patent application laid-open No. 2015-27260

Patent document 6: japanese patent application laid-open No. 2012-77000

Patent document 7: japanese patent laid-open No. 4-149194

Patent document 8: japanese patent laid-open No. 2007-197328

Patent document 9: japanese patent laid-open No. 60-153938

Patent document 10: japanese patent laid-open No. 11-130651

Disclosure of Invention

Technical problem to be solved by the invention

The technical problem of the invention is to find new physiological effects on phosphatidylinositol and provide new application.

Another object of the present invention is to provide a complex capable of easily dispersing phosphatidylinositol in water.

In addition, the inventors of the present invention found that even in the method using a polyol, the dispersibility of phosphatidylinositol in water is very low in the case of the polyol alone. Accordingly, another technical problem of the present invention is to provide a technique capable of dispersing phosphatidylinositol in water easily and stably.

Technical scheme for solving technical problems

As a result of intensive studies to solve the above-mentioned problems, the inventors of the present invention have found that phosphatidylinositol has various physiologically active actions, and have completed the present invention. In particular, a composition containing phosphatidylinositol at a high concentration obtained by a method comprising a predetermined step has an extremely excellent physiologically active effect.

Namely, the present invention provides the following whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-relieving agent, wrinkle-improving agent, complex, cosmetic and external preparation for skin.

Item 1.

A whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-relieving agent or wrinkle-improving agent containing phosphatidylinositol.

Item 2.

The agent according to claim 1, wherein the phosphatidylinositol is obtained by a method comprising the steps (1) to (3) in this order, and the agent is a composition containing 40 to 75% by weight of phosphatidylinositol,

(1): a step of allowing a phosphatidylinositol-free substrate-specific phospholipase B to act on lecithin;

(2): extracting phosphatidylinositol with an organic solvent;

(3): and a step of precipitating and recovering phosphatidylinositol using a hydrophilic solvent.

Item 3.

The agent according to item 2, wherein,

the phospholipase B is derived from Candida cylindracea (Candida cylindracea), penicillium shamen (Penicillium camanbertti), penicillium roqueforti (Penicillium Roqueforti), or Rhizopus oryzae (Rhizu oryzae).

Item 4.

A composite, characterized in that:

for preparing an emulsified or solubilized composition, wherein the composition is obtained by removing an organic solvent from a dispersion or solution in which the following components (A1) to (A3) are uniformly dispersed or dissolved in the organic solvent, and simultaneously precipitating the components (A1) to (A3);

(A1) Phosphatidylinositol,

(A2) Lecithin (L),

(A3) Sterols.

Item 5.

The complex according to item 4, wherein,

the component (A1) is a composition containing 40 to 75% by weight of phosphatidylinositol obtained by a method comprising the following steps (1) to (3) in this order,

(2): extracting phosphatidylinositol with an organic solvent;

Item 6.

The complex according to item 4 or 5, wherein,

the component (A2) is lecithin having a phosphatidylcholine content of 50 to 99% by weight.

Item 7.

The complex according to any one of claim 4 to 6, wherein,

the component (A2) is a mixture of hydrogenated lecithin and non-hydrogenated lecithin.

Item 8.

The complex according to any one of claim 4 to 7, wherein,

the total content of the components (A1) and (A2) in the composite is 60 to 99 wt%,

the content of the component (A3) is 1 to 40% by weight, and,

the weight ratio of the components (A1) to (A2) is 5: 95-50: 50.

item 9.

The complex according to any one of claim 4 to 7, wherein,

also contains antioxidant substances as component (A4),

the complex is obtained by removing the organic solvent from a dispersion or solution in which the components (A1) to (A4) are uniformly dispersed or dissolved in the organic solvent to simultaneously precipitate the components (A1) to (A4),

the total content of the components (A1) and (A2) in the composite is 40 to 98.99 wt%, the content of the component (A3) is 1 to 40 wt%, the content of the component (A4) is 0.01 to 20 wt%, and the weight ratio of the components (A1) to (A2) is 5: 95-50: 50.

Item 10.

A cosmetic or skin external preparation comprising the complex according to any one of claims 4 to 9.

Item 11.

A cosmetic or skin external preparation contains the following components (A) - (C).

(A) A composition comprising the following components (A1) and (A2):

(A1) Phosphatidylinositol,

(A2) Lecithin;

(B) A polyol;

(C) And (3) water.

Item 12.

The cosmetic or dermatological external preparation according to item 11, wherein,

the component (A1) is a composition containing 40 to 75% by weight of phosphatidylinositol obtained by a method comprising the steps (1) to (3) described below in this order.

(2): extracting phosphatidylinositol with an organic solvent;

Item 13.

The cosmetic or skin external preparation according to item 11 or 12, wherein,

Item 14.

The cosmetic or skin external preparation according to any one of claims 11 to 13, wherein,

Item 15.

The cosmetic or skin external preparation according to any one of claims 11 to 14, wherein,

As the component (A), a steroid as the component (A3) is also contained.

Item 16.

The cosmetic or skin external preparation according to any one of claims 11 to 15, wherein,

the composition (A) further contains an antioxidant substance as the component (A4).

Item 17.

The cosmetic or skin external preparation according to item 15, wherein,

the component (A) is a complex according to any one of items 4 to 8.

Item 18.

The cosmetic or skin external preparation according to item 16, wherein,

the component (A) is the complex according to item 9.

Item 19.

The cosmetic or dermatological external preparation according to any one of claims 11 to 18, wherein,

the content of the component (A) is 0.001 to 5% by weight, and the weight ratio of the component (A) to the component (B) is 1:5 to 1:200.

item 20.

The cosmetic or skin external preparation according to any one of claims 11 to 19, wherein,

the component (B) contains at least 1 selected from the group consisting of 1, 2-pentanediol, 1, 2-hexanediol, and isohexanediol (hexide).

Item 21.

The cosmetic or skin external preparation according to any one of claims 11 to 20, wherein,

and a nonionic surfactant as component (D).

Item 22.

The cosmetic or dermatological external preparation according to item 21, wherein,

the weight ratio of the components (A) to (D) is 1:0.1 to 1:10.

Item 23.

The cosmetic or dermatological external preparation according to item 21 or 22, wherein,

the component (D) is at least 1 selected from the group consisting of fatty acid glycerides, polyglycerin fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid glycerides, polyoxyethylene fatty acid sorbitan esters, polyoxyethylene fatty acid esters, and polyoxyethylene alkyl ethers.

Item 24.

The cosmetic or dermatological external preparation according to any one of claims 11 to 23, which has transparency in appearance.

ADVANTAGEOUS EFFECTS OF INVENTION

Phosphatidylinositol has excellent physiological activities such as whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect and wrinkle improving effect.

In addition, by using the complex of the present invention, phosphatidylinositol can be easily dispersed in water. In addition, the emulsion or dissolvable composition obtained has good dispersion stability. The complex of the present invention can exhibit excellent physiological activities such as whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect, and wrinkle improving effect, and is more surprisingly excellent in effect when used as a complex.

The cosmetic or skin external preparation of the present invention enables easy and stable dispersion of phosphatidylinositol in water.

Drawings

FIG. 1 is a graph showing the wrinkle-improving effect of phosphatidylinositol.

Detailed Description

The present invention relates to a phosphatidylinositol-containing whitening agent, a collagen production promoter, a hyaluronic acid production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent, and a wrinkle-improving agent.

Phosphatidylinositol is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn, palm, etc., and is contained in lecithin extracted from these plants. In the present invention, such lecithin may be used as it is, or a composition having an increased PI content may be used by solvent separation from such lecithin, column purification, or the use of an enzyme method described later. Specifically, the method using the enzyme includes the following steps (1) to (3).

(1): a step of allowing a phospholipase B having substrate specificity, which does not substantially act on PI, to act on lecithin;

(2): extracting PI with an organic solvent;

(3): and a step of precipitating and recovering the PI using a hydrophilic solvent.

The composition containing Phosphatidylinositol (PI) at a high concentration (hereinafter, simply referred to as a high-concentration PI composition) obtained by the above-described method using an enzyme is obtained by a method comprising the steps (1) to (3), and details thereof will be described below.

Examples of the lecithin used in the step (1) of producing the high-concentration PI composition include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cotton seed, corn, rice, barley, and egg yolk, and hydrogenated products thereof. These may be used alone or in combination of 2 or more. Among them, lecithin derived from plants is preferably used, more preferably from soybean or sunflower is used, and most preferably from soybean is used.

The phospholipase B having substrate specificity used in the step (1) of producing the high-concentration PI composition will be described. Phospholipase B (hereinafter also abbreviated as plb.) is a generic term for enzymes having an activity of acting on fatty acids bonded to the α -and β -positions of a glyceryl in glycerophospholipids through ester bonds and hydrolyzing the fatty acids. The PLB used in the present invention preferably has a substrate specificity that does not substantially act on PI but specifically acts on phospholipids such as PC, PE, PS, PA other than PI. As the phospholipase B, enzymes derived from microorganisms such as candida cylindracea described in patent document 4, penicillium salkii, penicillium roquefortii, and rhizopus oryzae described in patent document 5 can be used. Most preferred among these are enzymes derived from candida cylindracea.

In the present specification, a substrate having a substrate specificity that does not substantially act on PI is defined as: when the PLB activity is measured using PI or PC as a substrate, and the activity ratio (relative activity) of PI to PC is determined, the activity ratio is 10% or less, preferably 5% or less. On the other hand, the ratio of activities (relative activities) of phospholipids (PE, PS, PA) other than PI to PC is 20 to 150%, preferably 30 to 100%, which is sufficiently higher than PI. The PLB activity can be measured by the method described in patent document 4.

The conditions for allowing phospholipase B (PLB) to act on lecithin in the step (1) of producing a high-concentration PI composition may be as described in patent document 4 or 5. Specifically, PLB is added in a range of 1000 ～ 100000000 units, more preferably 2000 to 5000000 units per 1kg of lecithin. Lecithin is prepared as an aqueous dispersion previously uniformly dispersed in water, preferably to which PLB is added. As a method of dispersing lecithin in water, for example, a homogenizer or the like is preferably used. The concentration of lecithin in the aqueous dispersion is not particularly limited as long as it can act on PLB, and is in the range of 1 to 20% by weight, preferably 5 to 10% by weight, and particularly preferably 6 to 8% by weight.

The pH at which lecithin and PLB are allowed to act is preferably adjusted to a pH in the range of 3 to 10, more preferably adjusted to a pH around 5.5 to 6.5 at which the activity of PLB is maximized. In this case, in order to maintain the pH constant, a buffer solution is preferably used, and the type of buffer solution is not particularly limited as long as it has a buffer capacity in the range of pH5.5 to 6.5.

In addition, it is also preferable to appropriately add an alkali solution to the reaction instead of using a buffer solution to control the pH of the reaction solution within a preferable range. The temperature conditions in this case may be set within a range in which PLB is not deactivated, and the upper limit is preferably 60℃and more preferably 45 ℃. The lower limit of the temperature conditions under which the action is performed is preferably 10 ℃, more preferably 30 ℃. The reaction time varies depending on the above-mentioned enzyme reaction conditions, and is usually 1 to 150 hours, so long as the residual amount of the substrate can be quantitatively grasped and the reaction can be stopped. After the completion of the reaction, PLB may be deactivated by heat treatment, pH treatment or the like.

By performing the step (1) in the above-described manner, phospholipids such as PC, PE, PS, and PA other than PI in lecithin are selectively hydrolyzed to form free fatty acids, and deacylated phospholipids such as glycerophosphorylcholine (hereinafter also simply referred to as gpc), phosphatidylethanolamine (hereinafter also simply referred to as gpe.), glycerophosphorylserine (hereinafter also simply referred to as gps), and glycerophosphate (hereinafter also simply referred to as gpa). On the other hand, PI can be left as it is without being hydrolyzed.

As the organic solvent used in the step (2) of producing the high-concentration PI composition, at least one selected from chloroform, methylene chloride, toluene, diethyl ether, ethyl acetate, heptane, hexane, and a mixed solution of these with at least one selected from isopropanol, ethanol, and the like can be used. Among them, at least one selected from ethyl acetate, heptane and hexane and a mixed liquid of these and ethanol are more preferable, and hexane or a hexane-ethanol mixed liquid is further preferable.

In the present specification, the extraction of PI in the production process (2) of the high-concentration PI composition is defined as: the above-mentioned organic solvent is added to the reaction solution in the step (1), and the mixture is allowed to stand so as to separate the reaction solution into an organic solvent phase and an aqueous phase, whereby PI remaining in the step (1) is extracted in the organic solvent phase. In this case, it is preferably carried out in the presence of an inorganic salt and/or a chelating agent. In step (2), the free fatty acid, which is the hydrolysis product of step (1), is also soluble in an organic solvent, and is thus extracted in the organic solvent phase. Further hydrolysate GPC, GPE, GPS, GPA and the like are soluble in water, and therefore remain in the aqueous phase, and these components are removed in step (2).

The hydrophilic solvent used in the step (3) of producing the high-concentration PI composition is preferably at least one selected from acetone, isopropyl alcohol, ethanol and methanol, a mixed solution of these with water, and the like, and more preferably acetone and/or ethanol, a mixed solution of these with water, and the like.

Specifically, the process of adding the hydrophilic solvent to the PI-extracted organic solvent solution obtained in the step (2) or the concentrate obtained by recovering the organic solvent from the solution is first performed. PI is insoluble in the above hydrophilic solvent, and thus PI can be precipitated by such an operation. The precipitated PI is separated from the hydrophilic solvent by a method such as filtration or centrifugation, and further dried, whereby the target high-concentration PI composition can be recovered as a powder. In this step, the free fatty acid is soluble in the hydrophilic solvent, and thus the free fatty acid is removed in this step.

The high-concentration PI composition obtained by the above-described procedure can be obtained as a composition containing 40 to 75 wt%, more preferably 45 to 70 wt% PI. Such a production method is more efficient and easier to scale than conventional methods such as solvent separation and column purification, and therefore is most suitable as a method for industrially obtaining a high-concentration PI composition at low cost. In addition to the composition produced by the above-described production method, the high-concentration PI composition used in the present invention is commercially available as Soybrain PI50 (Soybrain PI 50) (manufactured by Unitec Foods) and such a commercially available product can be preferably used in the present invention.

The high-concentration PI composition obtained by the method comprising the steps (1) to (3) also contains components other than PI. Specifically, the inventors of the present invention have found that the components in the composition are separated by column chromatography and analyzed by various analytical instruments, and as a result, they contain about 3 to 10% by weight of sterol glucoside, about 2 to 8% by weight of phosphatidylethanolamine, about 0.1 to 2% by weight of phosphatidic acid, and about 1 to 5% by weight of triglyceride, and further contain about 15 to 35% by weight of unidentified components. Therefore, it is difficult to clearly define all components of the high-concentration PI composition obtained by the method including the steps (1) to (3), and the composition should be defined according to the production method.

As shown in examples described later, phosphatidylinositol has excellent physiological activities such as whitening, collagen production promoting, hyaluronic acid production promoting, intracellular active oxygen scavenging, irritation relieving and wrinkle improving. Therefore, these effects can be utilized as active ingredients of a whitening agent, a collagen production promoter, a hyaluronic acid production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent or a wrinkle-improving agent. Such a physiologically active effect is more excellent in the high-concentration PI composition obtained by the above-described method comprising the steps (1) to (3) than in phosphatidylinositol alone, presumably due to the influence of each component (including unidentified components) other than PI contained in the high-concentration PI composition.

The blending amount of PI in the whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention is not particularly limited, but is preferably 0.01 to 99% by weight, more preferably 0.1 to 90% by weight. The amount to be blended can be appropriately designed depending on the dosage form or the mode of administration.

Examples of methods for administering the whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention to a living body include oral administration, administration by injection, subcutaneous administration and the like. The amount to be administered is not particularly limited as long as the effect of the present invention can be obtained, and may be appropriately adjusted depending on the formulation form, site of application, age, sex, and the like of the preparation.

The whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention may be used as they are, or may be dissolved, dispersed or mixed in a usual base, for example, water, gel, polyol, vaseline, paraffin, vegetable oil, silicone oil or the like. In addition, various additives may be used in combination as needed. The additive that can be used is not particularly limited as long as it is an additive that is generally used to obtain a desired dosage form, and may be used by appropriately selecting known additives such as excipients, colorants, tackifiers, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, humectants, and pH adjusters. Alternatively, the active ingredient exhibiting the desired effect may be formulated and administered as a component of a pharmaceutical or cosmetic product. In the case of pharmaceuticals, the pharmaceutical composition may be formulated into oral preparations such as tablets, capsules, granules, powders, liquids, suspensions, etc.; external preparations such as skin external preparations, patches, eye drops, nasal drops, oral preparations, and suppositories; the preparation can be formulated into non-oral preparation such as drop and injection. In the case of cosmetics, it can be used in skin cosmetics such as astringent, skin care liquid (conditioner), gel, lotion, skin care liquid, cream, facial mask, facial cleanser, and body cleaner; make-up cosmetics such as foundations, lipsticks, mascara solutions, and the like; hair cosmetics such as shampoo, hair conditioner, hair spray, hair wax, styling lotion, dyeing lotion, hair beautifying agent, and hair tonic are added.

The whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention may be used in combination with a component having the same physiological activity, blood circulation promoter and the like. By combining such components, the effects of the present invention can be synergistically exhibited.

Examples of the whitening agent that can be used in combination include hydroquinone glycoside such as β -arbutin and α -arbutin, and esters thereof; ascorbyl phosphate salts such as ascorbic acid, sodium ascorbyl phosphate, and magnesium ascorbyl phosphate; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexyl glyceryl ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; tranexamic acid, cetyl tranexamic acid, and tranexamic acid amide; polyphenols such as brown algae polyphenols, curcumin, anthocyanin, procyanidine, catechin, ellagic acid, and apple polyphenols; nicotinamide, kojic acid, ellagic acid, 4-methoxysalicylic acid, linoleic acid, ferulic acid, placenta extract, glutathione, oryzanol, butylresorcinol, glabridin, resveratrol, lipoic acid, glucosylceramide, ergothioneine, phyllitol, hinokitiol, cysteine, gentisic acid, mevalonic acid, gallic acid, ornithine, glucosylrutin; and plant extracts having an effect of matricaria, licorice, saxifrage, mulberry, angelica, sanguisorba, paeonia, scutellaria baicalensis, hypericum, polygonum cuspidatum, tea, perilla, peach leaf, snow grass, japanese tripe, aloe, achillea, yarrow, through-leaf eupatorium, kudzu root, arnica, bearberry, asarum, rose fruit, asparagus, platycodon grandiflorum, thyme, horse chestnut, honeysuckle, mugwort, waxberry, raspberry, caraway leaf, cynara scolymus leaf, apricot kernel, lychee seed, broccoli bud, cinchona, polymerized grass, almond, gardenia, kuh-seng, spruce, ophiopogon root, pink pluma, needle cherry, clove, rose, coix seed, tilia, sesame, swertia, rehmannia, peppermint, gentian, caraway, heart, ginger, althea (althea), hyoscyama, grape seed, shrubus, evening primrose seed, kiwi seed and the like.

Specific examples of the collagen production promoter that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexyl glyceryl ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; nicotinamide, glutathione, cysteine, crocetin, sericin, geraniol (geraniol), glyceroglycosides, lactoferrin, procyanidins, pantothenic acid, panthenol, soyasaponin, resveratrol, isoflavones, coenzyme Q10, chondroitin sulfate, acetylglucosamine, glycerophosphorylcholine, hydrolyzed hyaluronic acid, collagen peptides, shell matrix (condhiolin) hydrolysates, 5' adenosine monophosphate, proline, glycine, arginine, aspartic acid, alanine; and plant extracts having collagen production promoting effect, such as hibiscus, licorice leaves, roman chamomile, sweet tea, hawthorn, impatiens balsamina, lotus leaves, kudzu root, sparassis crispa, chlorella, bear's bamboo, burdock, sophorae radix, cabbage heart, loquat leaves, perilla, pea, mulberry leaf, thyme, spruce, basil, dayflower, platycladi seed, cassia seed, snakegourd seed, garden burnet, kuh-seng, persimmon, peony, perilla, dried orange peel, mallow, ginger, chamomile, strawberry seeds, swertia herb, soybean, wheat, ginseng, coix seed, fangku, cardamon, rosemary, sage, and the like.

Examples of the hyaluronic acid production promoter that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexylglycerin ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; nicotinamide, carotenes, tocopherols, tocotrienols, chondroitin sulfate, acetylglucosamine, glycerophosphorylcholine, glyceroglycosides, hydrolyzed hyaluronic acid, collagen peptides, sitosterol, carnosine, creatine, phytic acid, N-methylserine, 3-methylcyclopentadecanone, saponins, genistein, soy flavone, phytol; and plant extracts having a hyaluronic acid production-promoting effect, such as marjoram, peppermint, apple mint, perilla, lemon, meng Sang, clathrum, bread fruit, papermulberry, paper mulberry, fig, ulva, mallow, pennywort, phellodendron, houttuynia cordata, achillea, almond, hawthorn, linseed, gardenia, nettle, strawberry seed, carambola, passion fruit, sea grape, saffron, camellia, pumpkin, towel gourd, asparagus, gynostemma pentaphylla, kuh-seng, dried orange peel, peony, persimmon, red sage, centella, puer tea, maitake mushroom, water shield, horsetail, pear, chamomile, and the like.

Examples of the intracellular active oxygen scavenger that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexylglycerin ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; vitamin E such as tocopherol, tocopheryl acetate, tocotrienol, etc.; carotenoids such as carotenes, lycopene, astaxanthin, and lutein; polyphenols such as brown algae polyphenols, curcumin, anthocyanin, procyanidine, catechin, ellagic acid, and apple polyphenols; coenzyme Q10, lipoic acid, lactoferrin, sesamin, lignans, chlorogenic acid, rutin; and plant extracts having intracellular active oxygen scavenging effect, such as radix Scutellariae, herba Rosmarini officinalis, fructus Eriobotryae, flos lupuli, flos Rosae Multiflorae, aspalathus linearis, hamamelis virginiana, thyme, radix Gentianae, peony, shell matrix, radix Sanguisorbae, flos Chrysanthemi, radix Dauci Sativae, herba Salvia officinalis (herba Lespedezae Cuneatae), fructus forsythiae, mori fructus, peppermint, pyracantha fortuneana, lemon, olive leaf, hypericum perforatum, grape leaf, angelica keiskei Koidz, catechu, semen Ginkgo, herba Urticae Cannabinae, herba Artemisiae Scopariae, mallow, oolong tea, fructus Rosae Davuricae, herba Rabdosiae Glaucocalycis, mugwort, flos Matricariae Chamomillae, glycyrrhrizae radix, flos Lonicerae, radix Sophorae Flavescentis, herba Erodii Geranii, black tea, herba Potentillae, herba Saponici, herba Centellae, folium Camelliae sinensis, flos Caryophylli, pericarpium Citri Tangerinae, sweet tea, herba Sidae Rhus, ramulus et Gemma Nitidae, fructus Avenae, herba Pogostemonis, herba Menthae, herba Melissae, herba Pogostemonis, folium.

Specific examples of the irritation-reducing agent that can be used in combination include mannitol erythritol, diethylene glycol dimer linoleate oligomer (dimer dilinoleate diethylene glycololigomer ester), malic acid diisostearate, N-acyl-L-glutamic acid, trehalose monofatty acid ester, fatty acid amide amine oxide, alkyl dimethyl amine oxide, phenylethyl glucoside, lauryl glucoside, ferulic acid glucoside, salicin, cedrol, polyethylene glycol, and polypropylene glycol; plant extracts with irritation relieving effects such as red flower, flower cage, peppermint, uncaria gambir, olive, etc.

Specific examples of the wrinkle-improving agent that can be used in combination include isopropyl-oxo-propyl-aminocarbonyl-pyrrolidine-carbonyl-methyl-propyl-aminocarbonyl-benzoyl-amino-acetic acid Na, retinol, nicotinamide, tranexamic acid, and 3-O-ethyl-ascorbic acid. Examples of the blood circulation accelerator include capsaicin, niacin, nicotinamide, tocopheryl nicotinate, tocopherol, tocopheryl acetate, oryzanol, dl-camphor, ginseng extract, ginkgo leaf extract, angelica extract, white birch extract, cinnamon extract, peony extract, saffron extract, wheat germ extract, ginger rhizome extract, capsicum extract, carrot extract, stachys sieboldii extract, mugwort extract, and angelica keiskei extract.

The present invention includes an invention relating to a complex for preparing an emulsified or dissolved composition, which is obtained by removing an organic solvent from a dispersion or solution in which the following components (A1) to (A3) are uniformly dispersed or dissolved in the organic solvent and precipitating the components (A1) to (A3) at the same time.

(A1) Phosphatidylinositol

(A2) Lecithin

(A3) Sterols

A complex is defined herein as a mixture of substances that maintains the chemical properties of each monomer, while exhibiting a physicochemical property as a complex. Examples of such physicochemical properties include changes in the formation of a complex with respect to temperature, and changes in the solubility and dispersibility with respect to a solvent.

The method for producing the composite of the present invention is as follows. First, the above components (A1), (A2) and (A3) are uniformly dispersed or dissolved in an organic solvent. The dispersion or dissolution may be carried out according to a usual method, and examples thereof include stirring, homogenization, and the like. In this case, if heating is performed, the heating can be efficiently performed.

Then, the organic solvent is removed from the organic solvent solution to precipitate phosphatidylinositol, lecithin and sterols at the same time. Examples of the method include a method of distilling the organic solvent solution under heating and/or reduced pressure to remove the organic solvent; a method of spray-drying the above organic solvent solution; and a method in which the organic solvent is frozen instantaneously with liquid nitrogen or the like and then lyophilized. The target complex can be obtained in the form of a semisolid, a solid or a powder by such a method, and is preferably obtained in the form of a powder from the viewpoint of the swelling rate when dispersed in water. Therefore, spray drying and freeze drying are preferably used as the production method, and further, as spray drying, the following apparatus (instantaneous vacuum dryer) is most preferably used: the organic solvent solution is supplied to a tubular heater at a constant speed, heated in the heater to evaporate the organic solvent, a mixture of a solid component and a vapor of the organic solvent is substantially formed, and the mixture is introduced into a vacuum chamber at a high speed to volatilize the organic solvent instantaneously. Patent document 7 describes the details of the present apparatus.

The organic solvent used in the production of the composite of the present invention is not particularly limited as long as it can uniformly dissolve or disperse all the components of the composite, and examples thereof include hydrocarbons such as pentane, hexane, heptane, and cyclohexane; halogenated hydrocarbons such as methylene chloride and chloroform; aromatic hydrocarbons such as benzene and toluene; lower alcohols such as methanol, ethanol, isopropanol, and t-butanol; esters such as methyl acetate and ethyl acetate. These organic solvents may be used alone or in combination of 2 or more. Among these, from the viewpoints of solubility, safety, and the like, hydrocarbons such as pentane, hexane, heptane, cyclohexane, and the like, and lower alcohols such as methanol, ethanol, isopropanol, tert-butanol, and the like are exemplified as preferable solvents.

The amount of the organic solvent used in the production of the composite of the present invention is not particularly limited as long as the entire component to be compounded is dissolved or uniformly dispersed, and the amount to be used may be appropriately changed depending on the solubility of the component to be compounded. In general, the amount of the compound may be 1 to 100 times by weight, preferably 3 to 50 times by weight, based on the total amount of the components to be compounded.

The phosphatidylinositol of component (A1) used in the complex of the present invention is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn and palm, and is contained in lecithin extracted from these plants. The PI-containing composition can be obtained in a high concentration by fractionation from such lecithin by solvent separation, column purification, or the above-described method using an enzyme, and such PI-containing composition can be used as component (A1) in the complex of the present invention. The high-concentration PI composition produced by the above-described method including the steps (1) to (3) may be preferably used, and as described above, the high-concentration PI-containing composition produced by such a method can be industrially and inexpensively obtained, and is commercially available as Soybrain PI50 (manufactured by unitefoods corporation). Such commercial products can be used in the present invention.

Examples of the lecithin as the component (A2) used in the composite of the present invention include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cotton seed, corn, rice, barley and egg yolk, and hydrogenated products thereof. These may be derivatives modified with polyoxyalkylene such as polyethylene glycol. These may be used alone or in combination of 2 or more. Generally, lecithin derived from natural plants contains about 30% by weight of phosphatidylcholine (hereinafter, also referred to as PC), and products having a PC content increased by solvent separation or the like are commercially available. In the present invention, from the viewpoint of improving dispersibility into water, a product having an increased PC content is preferably used, and the PC content in the component (A2) is preferably 50 to 99% by weight, more preferably 70 to 99% by weight. In addition, plant-derived lecithin contains about 10 to 20 wt% PI, and in lecithin with an increased PC content, PI is removed during the separation process, so PI is hardly contained. Therefore, in order to obtain a phospholipid composition having a high PC content and containing PI, it is preferable to mix a composition containing a high concentration of PI with lecithin having an increased PC content. Lecithin obtained from egg yolk naturally contains about 70 wt% of PC (no PI), and can be preferably used as the component (A2), and in view of the natural intention of consumers, lecithin derived from plant sources is preferably used. In addition, from the viewpoint of improving the feel of use when dispersing the complex of the present invention in water, it is preferable to use a mixture of hydrogenated lecithin and non-hydrogenated lecithin as the component (A2). As the mixing ratio of hydrogenated lecithin and non-hydrogenated lecithin, 99:1 to 70:30, more preferably 97:3 to 80:20.

In the present invention, the component (A2) is used for the purpose of assisting the dispersion of the component (A1). The blending ratio of the components (A1) and (A2) used in the present invention is not particularly limited, and is preferably 5 in terms of weight ratio from the viewpoint of sufficiently exhibiting the dispersibility and physiologically active effects of the complex of the present invention in water: 95-50: 50, more preferably 10: 90-30: 70.

specific examples of sterols of component (A3) used in the complex of the present invention include animal-derived sterols such as cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, and desmosterol; plant-derived sterols such as stigmasterol, sitosterol, brassicasterol and phytosterols of mixtures of these; sterols derived from microorganisms such as ergosterol; gamma-oryzanol; ursolic acid; glycyrrhetinic acid (Glycyrrhetinic acid); and their esterified products. These sterols may be used alone or in combination of 2 or more. In the present invention, the component (A3) is used to improve the dispersion stability of the resulting emulsified or solubilized composition. Among these sterols, cholesterol, phytosterin and γ -oryzanol are exemplified as preferable examples from the viewpoint of sufficiently exhibiting the effects of the present invention.

The compound of the present invention may further contain an antioxidant substance as component (A4) for the purpose of improving the storage stability of the compound or an emulsified or solubilized composition obtained by dispersing the compound in water. Specific examples of the antioxidant substance include: tocopherol and its derivatives, tocotrienol and its derivatives, gallic acid and its derivatives, ascorbic acid and its derivatives, vitamin A, carotenoids, lipoic acid, coenzyme Q10, panthenol, butylhydroxytoluene, butylhydroxyanisole, etc. Among these, tocopherol and its derivatives, carotenoids, lipoic acid, and coenzyme Q10 are exemplified as preferable examples.

When the composite of the present invention is composed of the components (A1), (A2) and (A3), the total content of the components (A1) and (A2) in the composite is preferably 60 to 99 wt%, the content of the component (A3) is preferably 1 to 40 wt%, the total content of the components (A1) and (A2) is more preferably 70 to 98 wt%, and the content of the component (A3) is preferably 2 to 30 wt%. When the composition further contains the component (A4), the total content of the components (A1) and (A2) in the composition is preferably 40 to 98.99 wt%, the content of the component (A3) is 1 to 40 wt%, the content of the component (A4) is 0.01 to 20 wt%, the total content of the components (A1) and (A2) is more preferably 70 to 97 wt%, the content of the component (A3) is 2 to 20 wt%, and the content of the component (A4) is 1 to 10 wt%.

By using the complex of the present invention thus obtained, phosphatidylinositol which is difficult to disperse in water alone can be easily dispersed in water, and a stable emulsified or solubilized composition can be obtained. The phosphatidylinositol as the component (A1) has excellent physiological activities such as hyaluronic acid production promoting action, intracellular active oxygen scavenging action, whitening action, collagen production promoting action and wrinkle improving action, and the complex of the present invention containing the phosphatidylinositol has excellent physiological activity, but, more surprisingly, the effect is more excellent when used as a complex.

When the compound of the present invention is dispersed in water, the compound may be directly added to water and mixed with stirring, and it is preferable to prepare the compound by a method in which the compound is dispersed in the polyol once, water is added to the resulting polyol dispersion with stirring, or the polyol dispersion is added to water with stirring. The emulsion-soluble composition prepared by such a method exhibits a transparent appearance and further exhibits improved dispersion stability. In the present invention, the appearance of transparent feeling means that the transparent feeling is observed from the back of the liquid when the sample is put in a glass bottle having a diameter of 3.5cm and the glass bottle is viewed from the side.

Therefore, such a polyol dispersion (premix composition) is prepared in advance, and the preparation of the emulsified or solubilized composition becomes easier. Further, when the components of the composite of the present invention are not compounded and are blended separately, they cannot be dispersed in water. On the other hand, when the dispersion is first carried out in the polyol and then carried out in water, the dispersion can be prepared by blending the dispersion, but the compound of the present invention is advantageous in that it requires a longer time for stirring and mixing for uniform dispersion of the polyol and the dispersion stability of the resulting emulsified or solubilized composition is sometimes poor, compared with the case of using the compound of the present invention.

Specific examples of the polyhydric alcohol to disperse the composite of the present invention include dihydric alcohols such as ethylene glycol, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, 2-methyl-1, 3-propanediol, 3-methyl-1, 3-butanediol (isoprene glycol), tetramethylene glycol, isohexylene glycol, octylene glycol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-heptanediol, 1, 2-octanediol, and 1, 2-decanediol; triols such as glycerin, trimethylolpropane, and 1,2, 6-hexanetriol; sugar alcohols such as sorbitol, xylitol, erythritol, maltitol, mannitol, and pentaerythritol; glycerol ethers such as ethyl glycerol, butyl glycerol, hexyl glycerol, and ethylhexyl glycerol; polyhydric alcohol polymers such as diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, diglycerol, triglycerol, tetraglycerol, and polyglycerol. These may be used alone or in combination of 2 or more. Among these, glycerin, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, isohexanediol, 1, 2-pentanediol, and 1, 2-hexanediol are exemplified as preferable examples, and it is particularly preferable that at least 1 selected from the group consisting of isohexanediol, 1, 2-pentanediol, and 1, 2-hexanediol must be contained from the viewpoints of transparency and dispersion stability of the obtained emulsified and solubilized composition.

The cosmetic or external skin preparation containing the complex of the present invention may contain, as necessary, an additive component usually blended in cosmetics, such as an oily base, a surfactant, an alcohol, a humectant, a polymer-thickening-gelling agent, an antioxidant, a preservative, a bactericide, a chelating agent, a pH adjuster-acid-base, an ultraviolet absorber, a whitening agent, a solvent, a exfoliating-dissolving agent, an antipruritic agent, an antiinflammatory agent, an antiperspirant, a cooling agent, an antihistamine, an astringent, a stimulant, a germinal agent-blood circulation accelerator, a reducing agent-oxidizing agent, a polymer powder, a hydroxy acid, vitamins and derivatives thereof, saccharides and derivatives thereof, organic acids, enzymes, nucleic acids, hormones, inorganic powders, fragrances, and pigments, etc., to the extent that the effects of the present invention are not impaired.

The present invention includes an invention relating to a cosmetic or skin external preparation containing the following components (a) to (C) as essential components.

(A) A composition comprising the following components (A1) and (A2),

(A1) Phosphatidylinositol,

(A2) Lecithin;

(B) A polyol;

(C) And (3) water.

The phosphatidylinositol of component (A1) used in the cosmetic or skin external preparation of the present invention is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn and palm, and is contained in lecithin extracted from these plants. The PI-containing composition can be obtained in a high concentration by fractionation from such lecithin by solvent separation, column purification, or the above-described method using an enzyme, and such PI-containing composition can be used as the component (A1) in the present invention. The high-concentration PI composition produced by the above-described method including the steps (1) to (3) may be preferably used, and as described above, the high-concentration PI-containing composition produced by such a method can be industrially and inexpensively obtained, and is commercially available as Soybrain PI50 (manufactured by unitefoods corporation). Such commercial products can be used in the present invention.

Examples of the lecithin as the component (A2) used in the cosmetic or skin external preparation of the present invention include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cottonseed, corn, rice, barley and egg yolk, and hydrogenated products thereof. These may be derivatives modified with polyoxyalkylene such as polyethylene glycol. These may be used alone or in combination of 2 or more.

Generally, lecithin derived from natural plants contains about 30% by weight of phosphatidylcholine, and products having a PC content increased by solvent separation or the like are commercially available. In the present invention, from the viewpoint of improving dispersibility, a product having an increased PC content is preferably used, and the PC content in the component (A2) is preferably 50 to 99% by weight, more preferably 70 to 99% by weight. In addition, the plant-derived lecithin contains about 10 to 20 wt% PI, and the lecithin having an increased PC content is removed during the separation process, so that it contains almost no PI. Therefore, in order to obtain a phospholipid composition having a high PC content and containing PI, it is preferable to mix a composition containing a high concentration of PI with lecithin having an increased PC content. Lecithin obtained from egg yolk naturally contains about 70 wt% of PC (no PI), and can be preferably used as component (A2), and in view of the natural intention of consumers, lecithin derived from plant is preferably used.

In addition, from the viewpoint of improving the feel of use of the cosmetic or dermatological agent of the present invention, it is preferable to use a mixture of hydrogenated lecithin and non-hydrogenated lecithin as the component (A2). As the mixing ratio of hydrogenated lecithin and non-hydrogenated lecithin, 99:1 to 70:30, more preferably 97:3 to 80:20.

in the present invention, the component (A2) is used for the purpose of assisting the dispersion of the component (A1). The blending ratio of the components (A1) and (A2) used in the present invention is not particularly limited, but is preferably 5 in terms of weight ratio from the viewpoint of sufficiently exhibiting dispersibility in water and physiological activity: 95-50: 50, more preferably 10: 90-40: 60.

in the cosmetic or skin external preparation of the present invention, sterols may be further blended as component (A3) in order to improve dispersion stability. Specific examples of the component (A3) include sterols derived from animals such as cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, and desmosterol; plant-derived sterols such as stigmasterol, sitosterol, brassicasterol and phytosterols of mixtures of these; sterols derived from microorganisms such as ergosterol; gamma-oryzanol; ursolic acid; glycyrrhetinic acid; and their esterified products. These may be used alone or in combination of 2 or more. Among these, cholesterol, phytosterin and γ -oryzanol are listed as preferred ingredients. The blending amount of the component (A3) is not particularly limited, and the ratio of the total blending amount of the components (A1) and (A2) to the blending amount of (A3) is preferably 200 in terms of weight ratio: 1 to 1:1, more preferably 100: 1-2: 1.

The cosmetic or external preparation of the present invention may further contain an antioxidant substance as component (A4) for the purpose of improving the storage stability of the cosmetic or external preparation. Specific examples of the antioxidant substance include: tocopherol and its derivatives, tocotrienol and its derivatives, gallic acid and its derivatives, ascorbic acid and its derivatives, vitamin A, carotenoids, lipoic acid, coenzyme Q10, panthenol, butylhydroxytoluene, butylhydroxyanisole, etc. Among these, tocopherol and its derivatives, carotenoids, lipoic acid and coenzyme Q10 are exemplified as preferable examples. The blending amount of the component (A4) is not particularly limited, and the ratio of the total blending amount of the components (A1) and (A2) to the blending amount of (A4) is preferably 400 in terms of weight ratio: 1-2: 1, more preferably 200:1 to 3:1.

the above-mentioned compound can be used as the component (a) used in the cosmetic or external skin preparation of the present invention.

The blending amount of the component (a) used in the cosmetic or skin external preparation of the present invention is not particularly limited, but is preferably 0.001 to 5% by weight, more preferably 0.005 to 2% by weight, and even more preferably 0.01 to 1% by weight, from the viewpoints of dispersion stability and transparency of the obtained cosmetic or skin external preparation.

The polyol of the component (B) used in the cosmetic or dermatological external preparation of the present invention is used for the purpose of dispersing the component (A) in water simply and stably. Specific examples of the component (B) include diols such as ethylene glycol, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, 2-methyl-1, 3-propanediol, 3-methyl-1, 3-butanediol (isoprene glycol), tetramethylene glycol, isohexylene glycol, octanediol, 1, 2-pentanediol (pentanediol), 1, 2-hexanediol, 1, 2-heptanediol, 1, 2-octanediol, and 1, 2-decanediol; triols such as glycerin, trimethylolpropane, and 1,2, 6-hexanetriol; sugar alcohols such as sorbitol, xylitol, erythritol, maltitol, mannitol, and pentaerythritol; glycerol ethers such as ethyl glycerol, butyl glycerol, hexyl glycerol, and ethylhexyl glycerol; polyhydric alcohol polymers such as diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, diglycerol, triglycerol, tetraglycerol, and polyglycerol. These may be used alone or in combination of 2 or more. Among these, glycerin, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, isohexanediol, 1, 2-pentanediol and 1, 2-hexanediol are exemplified as preferable examples from the viewpoint of dispersibility of the component (A) in water. In addition, from the viewpoints of transparency and dispersion stability of the obtained cosmetic or skin external preparation, it is particularly preferable that at least 1 selected from the group consisting of isohexanediol, 1, 2-pentanediol and 1, 2-hexanediol must be contained. By containing such an essential polyol, a cosmetic or skin external preparation excellent not only in initial dispersibility but also in transparency and dispersion stability can be obtained. In order to obtain a cosmetic or skin external preparation having transparency in appearance, it is desirable that such an essential polyol is contained in the component (B) at a concentration of 20% by weight or more, preferably 25% by weight or more, and most preferably 28% by weight or more.

The blending ratio of the components (a) and (B) used in the cosmetic or skin external preparation of the present invention is preferably 1 in terms of weight ratio from the viewpoint of obtaining a cosmetic or skin external preparation excellent in transparency and dispersion stability: 5 to 1:200, more preferably set to 1:10 to 1:150.

the water as the component (C) used in the cosmetic or external skin preparation of the present invention is not particularly limited as long as it can be used in usual cosmetics, and purified water, ion-exchanged water, distilled water, natural water, deep sea water, hydrogen-rich water, and the like can be used. The water may be water having its pH adjusted by an acid, a base, a buffer, a chelating agent, or the like, or water to which a preservative is added.

In the cosmetic or skin external preparation of the present invention, a nonionic surfactant may be further blended as component (D) in order to improve transparency and dispersion stability of the obtained cosmetic or skin external preparation. Specific examples of the component (D) include fatty acid glycerides, polyglycerin fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid glycerides, polyoxyethylene fatty acid sorbitan esters, polyoxyethylene fatty acid esters, and polyoxyethylene alkyl ethers. These may be used alone or in combination of 2 or more. Among these, fatty acid glycerides, polyglycerol fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid sorbitan esters, and polyoxyethylene alkyl ethers are cited as preferable examples.

More specific examples of the fatty acid glyceride of the component (D) include monoesters of fatty acids having 8 to 22 carbon atoms and glycerin. Among them, preferable examples include caprylic acid glyceride, capric acid glyceride, lauric acid glyceride, myristic acid glyceride, palmitic acid glyceride, stearic acid glyceride, oleic acid glyceride, isostearic acid glyceride, behenic acid glyceride, and the like, and most preferable examples are caprylic acid glyceride, capric acid glyceride, and lauric acid glyceride.

More specific examples of the polyglycerin fatty acid ester of the component (D) include monoesters, diesters, triesters and tetraesters of fatty acids having 8 to 22 carbon atoms with polyglycerins preferably having a polymerization degree of 2 to 20, more preferably having a polymerization degree of 6 to 12. Among them, preferable examples include: caprylic acid polyglycerin ester, capric acid polyglycerin ester, lauric acid polyglycerin ester, myristic acid polyglycerin ester, palmitic acid polyglycerin ester, stearic acid polyglycerin ester, oleic acid polyglycerin ester, isostearic acid polyglycerin ester, behenic acid polyglycerin ester, dicaprylic acid polyglycerin ester, dicaprac acid polyglycerin ester, dilaurate polyglycerin ester, dimyristate polyglycerin ester, distearic acid polyglycerin ester, dioleic acid polyglycerin ester, diisostearic acid polyglycerin ester, behenic acid polyglycerin ester, tricaprylin, trioleate polyglycerin ester, triisostearic acid polyglycerin ester, and tricaprin polyglycerin ester, particularly preferably caprylic acid polyglycerin ester, capric acid polyglycerin ester, lauric acid polyglycerin ester, dicaprac acid polyglycerin ester, and dilaurate polyglycerin ester.

More specific examples of the sucrose fatty acid ester of the component (D) include monoesters, diesters, triesters and tetraesters of fatty acids having 8 to 22 carbon atoms with sucrose. Among them, as preferable examples, there can be cited sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, sucrose oleate, sucrose behenate, sucrose erucate, sucrose dilaurate, sucrose dimyristate, sucrose dipalmitate, sucrose distearate, sucrose dioleate, sucrose dibehenate, sucrose distearate, sucrose trilaurate, sucrose trimyristate, sucrose tripalmitate, sucrose tristearate, sucrose trioleate, sucrose trilhenate, sucrose trilerucate, and the like, with preference given to sucrose laurate, sucrose myristate, sucrose palmitate, sucrose dilaurate, sucrose dimyristate, and sucrose dipalmitate.

The mannitol erythritol lipid used as the component (D) is a generic term for compounds represented by the following general formula (1), and more specific examples thereof include: r of the general formula (1) ₁ And R is ₂ Is acyl, R ₃ And R is ₄ Is acetyl, R ₅ MEL-a of a compound that is hydrogen R of the general formula (1) ₁ And R is ₂ Is acyl, R ₃ Is hydrogen, R ₄ Is acetyl, R ₅ MEL-B of a compound that is hydrogen; r of the general formula (1) ₁ And R is ₂ Is acyl, R ₃ Is acetyl, R ₄ Is hydrogen, R ₅ MEL-C of a compound that is hydrogen; r of the general formula (1) ₁ And R is ₂ Is acyl, R ₃ And R is ₄ Is hydrogen, R ₅ MEL-D, a compound that is hydrogen. Among these, MEL-B or MEL-C is preferred, and MEL-B is most preferred.

(wherein R is ₁ 、R ₂ Represents hydrogen or an aliphatic acyl group having 2 to 24 carbon atoms (but not simultaneously hydrogen). In addition, R ₃ 、R ₄ Represents hydrogen or acetyl, R ₅ Represents hydrogen or an aliphatic acyl group having 2 to 24 carbon atoms. )

More specific examples of the polyoxyethylene fatty acid glyceride of the component (D) include monoesters, diesters, and triesters of polyoxyethylene glycerol adducts having an addition mole number of 4 to 200, more preferably 8 to 100, to polyoxyethylene (E.O) and fatty acids having 8 to 22 carbon atoms. Among them, polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate, polyoxyethylene myristate, polyoxyethylene palmitate, polyoxyethylene stearate, polyoxyethylene oleate, polyoxyethylene isostearate, polyoxyethylene dicaprylate, polyoxyethylene dicaprate, polyoxyethylene dilaurate, polyoxyethylene dimyristate, polyoxyethylene dipalmitate, polyoxyethylene distearate, polyoxyethylene dioleate, polyoxyethylene diisostearate, polyoxyethylene trioctanoate, polyoxyethylene tricaprate, polyoxyethylene trilaurate, polyoxyethylene trimyristate, polyoxyethylene tripalmitate, polyoxyethylene tristearate, polyoxyethylene trioleate, polyoxyethylene triisostearate and the like are particularly preferable, and polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate and polyoxyethylene laurate are most preferable.

More specific examples of the polyoxyethylene fatty acid sorbitan ester of the component (D) include monoesters, diesters, and triesters of sorbitan polyoxyethylene adducts having an addition mole number of preferably 4 to 200, more preferably 8 to 100, with fatty acids having 8 to 22 carbon atoms, and the like, to polyoxyethylene (E.O). Among them, polyoxyethylene caprylate sorbitan ester, polyoxyethylene caprate sorbitan ester, polyoxyethylene laurate sorbitan ester, polyoxyethylene myristate sorbitan ester, polyoxyethylene palmitate sorbitan ester, polyoxyethylene stearate sorbitan ester, polyoxyethylene oleate sorbitan ester, polyoxyethylene isostearate sorbitan ester, polyoxyethylene dioctanoate sorbitan ester, polyoxyethylene dicaprate sorbitan ester, polyoxyethylene dilaurate sorbitan ester, polyoxyethylene dimyristate sorbitan ester, polyoxyethylene dipalmitate sorbitan ester, polyoxyethylene distearate sorbitan ester, polyoxyethylene dioleate sorbitan ester, polyoxyethylene diisostearate sorbitan ester, polyoxyethylene trioctanoate sorbitan ester, polyoxyethylene tridentate sorbitan ester, polyoxyethylene trilaurate sorbitan ester, polyoxyethylene trimyristate sorbitan ester, polyoxyethylene tripalmitate sorbitan ester, polyoxyethylene tristearate sorbitan ester, polyoxyethylene trioleate sorbitan ester, and polyoxyethylene tristearate sorbitan ester and the like are particularly preferable, most preferred are polyoxyethylene sorbitan octoate, polyoxyethylene sorbitan decanoate, polyoxyethylene sorbitan laurate, polyoxyethylene sorbitan oleate, and polyoxyethylene sorbitan isostearate.

More specific examples of the polyoxyethylene fatty acid ester of the component (D) include monoesters and diesters of polyoxyethylene (E.O) having preferably 4 to 200, more preferably 8 to 100, and fatty acids having 8 to 22 carbon atoms, in terms of the molar number of addition to the polyoxyethylene. Among them, polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate, polyoxyethylene myristate, polyoxyethylene palmitate, polyoxyethylene stearate, polyoxyethylene oleate, polyoxyethylene isostearate, polyoxyethylene behenate, polyoxyethylene dicaprylate, polyoxyethylene dicaprate, polyoxyethylene dilaurate, polyoxyethylene dimyristate, polyoxyethylene dipalmitate, polyoxyethylene distearate, polyoxyethylene dioleate, polyoxyethylene diisostearate, polyoxyethylene behenate and the like are particularly preferable, and polyoxyethylene caprylate, polyoxyethylene caprate, and polyoxyethylene laurate are most preferable.

More specific examples of the polyoxyethylene alkyl ether of the component (D) include those obtained by adding polyoxyethylene (E.O) to a lipophilic compound having a hydroxyl group, such as an alcohol having 8 to 32 carbon atoms or castor oil, preferably 4 to 200 moles, more preferably 8 to 100 moles. Among them, polyoxyethylene decyl ether, polyoxyethylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene myristyl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene isostearyl ether, polyoxyethylene behenyl ether, polyoxyethylene cholesterol ether, polyoxyethylene phytosterol ether, and hydrogenated castor oil polyoxyethylene ether are particularly preferable, and polyoxyethylene decyl ether, polyoxyethylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene cholesterol ether, polyoxyethylene phytosterol ether, and hydrogenated castor oil polyoxyethylene ether are most preferable.

The blending amount of the component (D) used in the cosmetic or skin external preparation of the present invention is preferably 1 in terms of the blending ratio of the components (a) and (D) from the viewpoint of obtaining a cosmetic or skin external preparation excellent in transparency and dispersion stability: 0.1 to 1:10, more preferably 1:0.2 to 1:5.

in the cosmetic or skin external preparation of the present invention, the appearance of transparency means that the transparent feeling of the back of the liquid can be seen through the liquid when the sample is put in a glass bottle having a diameter of 3.5cm and viewed from the side. When turbidity was measured by a spectrophotometer, a sample was placed in a sample cell having a thickness of 1cm, and the transmittance was 60% or more when measured at a wavelength of 600 nm.

As a method for producing the cosmetic or skin external preparation of the present invention, first, the following methods are listed: the components (A) and (B) or the components (A), (B) and (D) are heated and mixed with stirring to prepare a polyol dispersion, and water is added to the obtained polyol dispersion with stirring. In this case, the polyol dispersion may be added to water while stirring. As described above, phosphatidylinositol is difficult to disperse in water when used alone, but by such a method, phosphatidylinositol can be dispersed in water easily and stably, and a cosmetic or skin external preparation excellent in transparency and dispersion stability can be obtained.

The phosphatidylinositol as the component (A1) of the present invention has excellent physiological activities such as hyaluronic acid production promoting action, intracellular active oxygen scavenging action, whitening action, collagen production promoting action and wrinkle improving action, and the cosmetic or skin external preparation of the present invention containing the PI also has excellent physiological activity.

The cosmetic or external skin preparation of the present invention may contain, if necessary, an additive component ordinarily incorporated in cosmetics, for example, at least 1 selected from the group consisting of oily bases, surfactants, alcohols, moisturizers, polymer-thickening-gelling agents, antioxidants, preservatives, bactericides, chelating agents, pH adjusting agents-acid-bases, ultraviolet absorbers, whitening agents, solvents, exfoliating-dissolving agents, antipruritics, anti-inflammatory agents, antiperspirant agents, cooling agents, antihistamines, astringents, stimulators, hair-growing agents-blood circulation promoters, reducing agents-oxidizing agents, polymer powders, hydroxy acids, vitamins and derivatives thereof, saccharides and derivatives thereof, organic acids, enzymes, nucleic acids, hormones, inorganic powders, perfumes, pigments, and the like, to the extent that the effects of the present invention are not impaired.

While the embodiments of the present invention have been described above, the present invention is not limited to these examples, and can be implemented in various ways without departing from the scope of the present invention.

Examples

Hereinafter, embodiments of the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

Evaluation of physiological Activity of phosphatidylinositol

The whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect, and wrinkle improving effect were confirmed on phosphatidylinositol by the following experiments. The phosphatidylinositol used in this test was a high-concentration PI composition (Soybrain PI50 from unitefoods) obtained by the above-described method including steps (1) to (3) and phosphatidylinositol obtained by separating only PI from the resultant product by column chromatography (hereinafter referred to as high-purity PI). The composition of each component contained in the Soybrain PI50 used this time was confirmed as the composition of table 1 by separation by column chromatography and analysis by analytical instruments such as HPLC, NMR and IR.

TABLE 1

Weight percent

Composition of the components	Composition of the composition
		Phosphatidylinositol (PI)	60
Phosphatidylethanolamine (PE)	5
		Phosphatidic Acid (PA)	1
Sterol glucosides	6
		Triglycerides (Triglycerides)	2
Unidentified	26

< melanogenesis inhibitory Effect >

B16F10 mouse melanoma cells were cultured in the medium to which each test sample was added at the concentrations described in table 2 for 72 hours. After completion of the addition culture, a 2N aqueous sodium hydroxide solution containing 10% dimethyl sulfoxide was added to the recovered cells, and the mixture was heated to 60℃to form a cell lysate. The absorbance at 450nm was measured for the obtained cell lysate, and the amount of melanin in the pigment cells was measured. Further, protein concentration of the cell lysate was quantified using Protein Assay Dye Reagent Concentrate (BIO-RAD) based on bovine serum albumin (Thermo scientific Co.) to calculate the amount of melanin per unit protein mass. As a control, the amount of melanin in the medium to which the test sample was not added was similarly measured. The results are shown in Table 2 as relative values when the amount of melanin in the control is 100%.

TABLE 2

Melanogenesis inhibitory effect

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: sample obtained by separating only PI from Soybrain PI50

< evaluation of promotion of collagen production >)

After normal human dermal fibroblasts were cultured in a medium to which each test sample was added at the concentrations shown in Table 3 for 72 hours, the amount of type I collagen in the supernatant of the medium was quantified by ELISA. As a control, the amount of type I collagen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 3 as relative values when the amount of type I collagen of the control was set to 100%.

TABLE 3

Evaluation of promotion of type I collagen production

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

< evaluation of promotion of hyaluronic acid production >

After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in table 4 for 72 hours, the amount of hyaluronic acid in the culture supernatant was quantified by ELISA. As a control, the amount of hyaluronic acid in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 4 as relative values when the amount of hyaluronic acid of the control was set to 100%.

TABLE 4

Evaluation of promotion of hyaluronic acid production

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: sample obtained by separating only PI from Soybrain PI50

< evaluation of intracellular active oxygen clearance >

After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in Table 5 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and then exposed to 2' -7' -dichlorofluorescein (Dichlorofluorescin) (SIGMA) containing fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes. Then, the sample was exposed to HBSS (-) containing 500. Mu.M hydrogen peroxide as active oxygen, and the amount of intracellular active oxygen after 1 hour was quantified by a fluorescence microplate reader (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 5 as relative values when the amount of active oxygen in the cells of the control was set to 100%.

TABLE 5

Evaluation of intracellular active oxygen elimination

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: sample obtained by separating only PI from Soybrain PI50

< evaluation of inhibition of SLS-inducible intracellular Activity

After normal human epidermal cells were cultured in a medium containing 10. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 6 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes, and the cells were allowed to take in the fluorescent probe, and the amount of active oxygen in the cells was quantified by a fluorescent enzyme-labeled instrument (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample (SLS alone) was not added was similarly quantified. The results are shown in Table 6 as relative values when the amount of active oxygen in the cells of the control was set to 100%.

TABLE 6

Evaluation of inhibition of SLS-inducible intracellular reactive oxygen species

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

< evaluation of inhibition of cytotoxicity caused by SLS >

After normal human epidermal cells were cultured in a medium containing 25. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 7 for 24 hours, they were stained with WST-8 (the same core chemical institute) and the cell viability was measured by absorbance (450 nm). The results are shown in Table 7 as relative values when the cell viability of the control (no SLS added and test sample) was 100%.

TABLE 7

Evaluation of inhibition of cytotoxicity by SLS

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: sample obtained by separating only PI from Soybrain PI50

From the results shown in tables 2 to 5, phosphatidylinositol has excellent whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect and intracellular active oxygen scavenging effect. The high-concentration PI composition of the present invention obtained by the method comprising the steps (1) to (3) gives a more excellent effect than the high-purity PI. In addition, it is suggested that exposure of SLS causes an increase in intracellular active oxygen through interaction with cell membranes, and is associated with induction of skin roughness. In addition, it is considered that the decrease in cell viability (cytotoxicity) due to SLS exposure is associated with stimulation. From the results shown in Table 6, it was found that phosphatidylinositol inhibited the increase in intracellular active oxygen caused by SLS, and from the results shown in Table 7, it was assumed that phosphatidylinositol had a stimulating effect of alleviating cytotoxicity by SLS.

< evaluation of wrinkle improvement >

The wrinkle-improving action was confirmed by following the method "instruction manual for evaluation of anti-wrinkle articles for obtaining new efficacy" formulated by the japan cosmetic society. 18 healthy adult females (35-58 years old and average 46.3 years old) were treated with the phosphatidylinositol-containing lotion described in Table 8 2 times in the morning and evening of 1 day on one half of the face, and the other half was not applied. Photographs of the outer corners of the eyes were taken on the first day (week 0), week 2 and week 4 of the test, and the wrinkle grade was judged from the obtained images by an expert skilled in evaluating wrinkles (score 0: no wrinkles; score 1: confirming a small number of insignificant shallow wrinkles; score 2: confirming a small number of significant shallow wrinkles; score 3: confirming significant shallow wrinkles). The results are shown in FIG. 1 as the change in wrinkle level.

TABLE 8

Weight percent

	Amount of blending
		The composite of example 3	0.2
Glycerol	2
		1, 2-pentanediol	3
Phenoxyethanol	0.2
		Purified water	94.6

From the results of fig. 1, the wrinkle grade did not change significantly with respect to the non-coated portions, and the wrinkle grade was significantly reduced at the portions to which the phosphatidylinositol-containing lotion was applied, and it was found that phosphatidylinositol had an excellent wrinkle-improving effect.

Evaluation of the inventive complexes

< manufacturing of composite >

The components (total 10 g) of the complex of the present invention were dissolved in 80g of t-butanol with the composition shown in Table 9, and then frozen instantaneously with liquid nitrogen, and lyophilized with a lyophilization apparatus (manufactured by Tokyo physical and chemical instruments, model FDU-2200). The pressure was set to 10Pa or less, and the cold trap temperature was set to-80 ℃. The complexes thus obtained were homogeneous pale yellow powders. In addition, as a comparison, a composite of the composition of table 10 was also prepared.

Preparation and evaluation of aqueous dispersion

Using the above-obtained composite, an aqueous dispersion was prepared with the composition shown in table 11. The initial dispersibility, transparency and dispersion stability of the obtained aqueous dispersion were evaluated by the following methods, and the results are shown in the following tables 9 and 10.

< initial dispersibility >)

The dispersion state immediately after the preparation of the aqueous dispersion was visually observed, and the initial dispersibility was evaluated based on the following evaluation criteria.

Uniform dispersion

X. Do not uniformly disperse

Transparency >

The obtained aqueous dispersion was placed in a glass bottle having a diameter of 3.5cm, and the appearance was visually observed from the side, and the transparency was evaluated based on the following evaluation criteria.

Back of liquid visible through liquid

Delta. The back of the liquid is slightly visible through the liquid

Back of the body where no liquid can be seen through the body

< dispersion stability >)

The resulting aqueous dispersion was subjected to a storage stability test at 50℃for 1 month, and the dispersion stability was evaluated on the basis of the following evaluation.

Even after storage

Delta. After storage, also dispersed substantially homogeneously

After storage, the polymer was not uniformly dispersed or precipitated

TABLE 9

Weight percent

/>

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 10

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 11

Weight percent

The preparation method comprises the following steps: no.1 and No.2 were previously stirred and mixed at 80℃to prepare a mixture (part A). No.3 and No.4 were uniformly dissolved at 80 ℃. Part A was added to part B with stirring, and the mixture was stirred with a homogenizer (75 ℃ C., 5000rpm,15 minutes) and cooled.

From the results of table 9, the aqueous dispersion prepared using the compound of the present invention was excellent in initial dispersibility, transparency and dispersion stability. Further, as a result of comparing the use feeling with the aqueous dispersion prepared with the compound of example 1 and example 2, the compound of example 2 in which the non-hydrogenated lecithin was blended was excellent in use feeling such as skin affinity feeling (top-binding) and penetrating feeling. In addition, the compound of example 2 and example 3 showed little change in hue and taste when stored at 50 ℃ for 2 weeks, as a result of comparison of the appearance. On the other hand, according to the results of table 10, the weight ratio of components (A1) and (A2) was 59:41, the compound of comparative example 1 and the compound of comparative example 2 having a blending amount of component (A3) of more than 40% by weight failed to produce a satisfactory aqueous dispersion, and the compound of comparative example 3 containing no component (A3) in the compound was excellent in initial dispersibility and transparency, but insufficient in dispersion stability. In addition, the compound of comparative example 4 having a low PC content in the component (A2) can be dispersed in an initial stage, but the transparency and dispersion stability are poor, and it is considered that the PC content in the component (A2) greatly affects the water dispersibility of the compound.

Preparation and evaluation of aqueous dispersion 2 >

Aqueous dispersions using the compounds of the present invention were prepared with the compositions shown in Table 12. The transmittance (sample cell thickness 1cm, wavelength 600 nm) of the obtained aqueous dispersion was measured as an index of transparency, and the results are shown in Table 12.

TABLE 12

Weight percent

The preparation method comprises the following steps: no.1 and No.2 were previously stirred and mixed at 80℃to prepare a premix composition. The obtained premix composition was added to the aqueous solutions of No.3 and No.4 dissolved at 80℃with stirring, stirred with a homogenizer (75℃5000rpm,15 minutes), and cooled.

From the results shown in Table 12, it was found that when the compound of the present invention was dispersed in water, the transparency of the dispersion liquid was improved by using 1, 2-pentanediol, 1, 2-hexanediol, and isohexanediol as the polyhydric alcohols. In addition, by using these, an aqueous dispersion having high transparency can be obtained even if another polyol is used.

The whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, and intracellular active oxygen scavenging effect of the complex of the present invention were confirmed by the following experiments.

< melanogenesis inhibitory Effect >

B16F10 mouse melanoma cells were cultured in the medium to which each test sample was added at the concentrations described in table 13 for 72 hours. After completion of the addition culture, a 2N aqueous sodium hydroxide solution containing 10% dimethyl sulfoxide was added to the recovered cells, and the mixture was heated to 60℃to form a cell lysate. The absorbance at 450nm was measured for the obtained cell lysate, and the amount of melanin in the pigment cells was measured. Further, protein concentration of the cell lysate was quantified using Protein Assay Dye Reagent Concentrate (BIO-RAD) based on bovine serum albumin (Thermo scientific Co.) to calculate the amount of melanin per unit protein mass. As a control, the amount of melanin in the medium to which the test sample was not added was similarly measured. The results are shown in Table 13 as relative values when the amount of melanin in the control was 100%.

TABLE 13

Melanogenesis inhibitory effect

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: composite of composition after component (A1) was removed from example 2

< evaluation of promotion of collagen production >)

After normal human dermal fibroblasts were cultured in the medium to which each test sample was added at the concentrations shown in Table 14 for 72 hours, the amount of type I collagen in the supernatant of the medium was quantified by ELISA. As a control, the amount of type I collagen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 14 as relative values when the amount of type I collagen of the control was set to 100%.

TABLE 14

Evaluation of promotion of type I collagen production

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: composite of composition after component (A1) was removed from example 2

< evaluation of promotion of hyaluronic acid production >

After culturing normal human epidermal cells in the medium to which each test sample was added at the concentrations shown in table 15 for 72 hours, the amount of hyaluronic acid in the supernatant of the medium was quantified by ELISA. As a control, the amount of hyaluronic acid in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 15 as relative values when the amount of hyaluronic acid of the control was 100%.

TABLE 15

Evaluation of promotion of hyaluronic acid production

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: composite of composition after component (A1) was removed from example 2

< evaluation of intracellular active oxygen clearance >

After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in Table 16 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes to allow the cells to take in the fluorescent probe. Then, the sample was exposed to HBSS (-) containing 500. Mu.M hydrogen peroxide as active oxygen, and the amount of intracellular active oxygen after 1 hour was quantified by a fluorescence microplate reader (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 16 as relative values when the amount of active oxygen in the cells of the control was set to 100%.

TABLE 16

Evaluation of intracellular active oxygen elimination

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: composite of composition after component (A1) was removed from example 2

< evaluation of inhibition of SLS-inducible intracellular Activity

After normal human epidermal cells were cultured in a medium containing 10. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 17 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes, and the cells were allowed to take in the fluorescent probe, and the amount of active oxygen in the cells was quantified by a fluorescent enzyme-labeled instrument (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 17 as relative values when the amount of active oxygen in the cells of the control was set to 100%.

TABLE 17

Inhibition of SLS-induced intracellular reactive oxygen species

* : the PI concentration in the medium is shown in brackets

**：Soybrain PI50

* **: composite of composition after component (A1) was removed from example 2

From the results in tables 13 to 17, it was found that the complex of the present invention has excellent whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect and intracellular active oxygen scavenging effect. The compound of the present invention is excellent in effect not only as compared with the case where the compound is not added, but also as compared with the case where the PI composition is used alone at a high concentration.

Evaluation of cosmetic or skin external preparation containing Components (A) to (C)

Lotions containing the components (a) to (C) of the present invention in the compositions shown in tables 18 to 22 were prepared by the following methods. The obtained lotions were evaluated for initial dispersibility, transparency and dispersion stability by the following methods, and the results are collectively shown in the lower column of each table.

< preparation method >)

The components (A) and (B) were previously mixed at 80℃with stirring to prepare a polyol dispersion. The obtained polyol dispersion was added to an aqueous solution of methylparaben and component (C) dissolved at 80℃in advance with stirring, and the mixture was stirred with a homogenizer (75℃at 5000rpm for 15 minutes) and cooled.

< initial dispersibility >)

The dispersion state immediately after the preparation of the obtained toning lotion was visually observed, and the initial dispersibility was evaluated based on the following evaluation criteria.

Uniform dispersion

X. Do not uniformly disperse

Transparency >

The transmittance of the cosmetic water (sample cell thickness 1cm, wavelength 600 nm) was measured using a spectrophotometer. The lotion was placed in a glass bottle having a diameter of 3.5cm, and the appearance was visually observed from the side, and the transparency was evaluated on the basis of the following evaluation.

Back of liquid visible through liquid

Delta. The back of the liquid is slightly visible through the liquid

Back of the body where no liquid can be seen through the body

< dispersion stability >)

The obtained toner was subjected to a storage stability test at 50℃for 1 month, and the dispersion stability was evaluated according to the following evaluation criteria.

Even after storage

Delta. After storage, also dispersed substantially homogeneously

After storage, the polymer was not uniformly dispersed or precipitated

TABLE 18

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 19

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 20

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 21

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 22

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

From the results in tables 18 to 20, it is clear that the component (A) can be easily and stably dispersed in water using the component (B). In particular, when 1, 2-pentanediol, 1, 2-hexanediol, or isohexanediol (an essential polyol) was used as the component (B), the transparency and dispersion stability were very excellent (examples 17 to 19). It is also clear that when the essential polyol is used alone, a water cosmetic excellent in transparency and dispersion stability can be obtained, and when the essential polyol is used in combination with other polyols poor in transparency or dispersion stability, a water cosmetic excellent in transparency and dispersion stability can be obtained (examples 23 to 27). In order to obtain a water lotion excellent in transparency, these essential polyols may be contained in the component (B) in an amount of 25 wt% or more (examples 28 to 30).

From the results in Table 21, it was found that when the ratio of component (A1) in component (A) was high, the dispersion was not possible in the initial stage (comparative example 6). When the ratio of the component (B) to the component (a) is low, the dispersion cannot be made in the initial stage (comparative example 7). From the results shown in Table 22, it was found that the component (A2) has high PC content and is excellent in transparency and dispersion stability (examples 35 to 37).

Evaluation of cosmetic or skin external preparation containing Components (A) to (D)

The lotions containing the components (a) to (C) and the component (D) of the present invention in the compositions of tables 23 to 25 were prepared by the following methods. The obtained lotions were evaluated for initial dispersibility, transparency and dispersion stability in the same manner as described above, and the results are also shown in the lower column of each table.

TABLE 23

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 24

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

TABLE 25

Weight percent

*1: soybrain PI50 manufactured by Unitecfoos Inc

From the results in tables 23 to 25, it is clear that the lotions of examples were excellent in transparency and dispersion stability as compared with lotions (comparative examples 8 and 9) containing no component (B) or (D). When the ratio of the component (A1) in the component (a) is high, the dispersion cannot be performed in the initial stage (comparative example 10), and when the PC content in the component (A2) is high, the transparency and dispersion stability are excellent (examples 50 and 52).

The following cosmetics were prepared using the compound of the present invention. The obtained cosmetic has excellent moisture retention and penetration feeling, and can prevent fine wrinkles and rough skin, and make skin look plump and bright.

Example 53 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm), to prepare a nanovesicle (nanovesicle) solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.

Example 54 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, the mixture was dispersed by using a high-pressure emulsifying machine (Microfluidizer, manufactured by MIZUHO Industrial Co., ltd.). After cooling, the pre-cooled C part was added to form a uniform solution.

Example 55 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.

Example 56 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a stirring paddle (500 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.

Example 57 whitening lotion

/>

(preparation method)

Mixing part B to prepare a viscous liquid. The portions A and C were heated to 70℃respectively, and the portion A was added to the portion C while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-mixed part B was added to form a uniform solution.

Example 58 gel toner

/>

(preparation method)

Part a was heated to about 70 ℃ to uniformly disperse it. Mix part C and stir thoroughly and heat to about 70 ℃ after mixing. The part B was stirred with a stirring paddle to prepare a mixed solution. Part C was added to part A, stirred at about 70℃using a homomixer, cooled to about 40℃and the mixture of part B was added.

EXAMPLE 59 transparent gel

/>

(preparation method)

Stirring the part A by using a stirring paddle to prepare a nano vesicle solution. Mixing the components C to obtain viscous liquid. Mixing part B to form a uniform solution. Part A and part B were added to part C and mixed well.

Example 60 Hair-growing agent

/>

(preparation method)

Example 61 two phase separated skin Care solution

/>

(preparation method)

Part a was heated to about 70 ℃ to allow uniform dissolution. Stirring part B to obtain viscous liquid. Parts A and B were added at about 50℃and stirred, and allowed to cool.

Example 62 whitening emulsion

/>

(preparation method)

The portions A and E were heated to about 70℃respectively, and dissolved uniformly. Stirring part B to obtain viscous liquid. Part C was heated to about 70℃to disperse it uniformly. After part A was added while stirring part C with a homogeneous disperser, part E was added while stirring. The portions D and B were added at about 50℃and stirred to be dissolved uniformly.

Example 63 emulsion

/>

(preparation method)

Mixing part A, part B and part D, and heating to about 70deg.C to uniformly dissolve and disperse. Mixing the components C, and stirring to obtain liposome solution. The emulsion was carried out by adding part D to part A while stirring with a homogeneous disperser and adding part B. After cooling, part C was added at about 50 ℃ and stirred, and cooled to about 40 ℃.

Example 64 skin Care cream

/>

(preparation method)

Mixing the part A and the part C respectively, and heating to about 70 ℃ to uniformly dissolve and disperse. Mixing part B, stirring to obtain viscous liquid. The emulsion was obtained by adding part A to part C while stirring with a homomixer. Cooling was performed, part B was added at about 50 ℃, stirred, and cooled to about 40 ℃.

Example 65 skin Care cream

/>

(preparation method)

Mixing part A, part B and part E, and heating to 70deg.C to make it dissolve and disperse uniformly. Mixing the components D, and stirring to obtain viscous liquid. Heating part C to about 70deg.C, mixing, and making into liposome. The part A was stirred with a homogeneous disperser, part B was added, and part E was added to emulsify the mixture. Cooling was performed, parts C and D were added at about 50 ℃ and stirred, cooling to about 40 ℃.

Example 66 skin Care cream

/>

(preparation method)

Mix part a and heat to about 70 ℃ to dissolve. Mixing part B, and stirring to obtain viscous liquid. Mixing part C, heating to about 70deg.C, and dispersing uniformly. Mixing part D, heating to about 70 ℃ to dissolve. The solution was added while stirring the solution in the part A with a homogenizer in the part C, and then the solution was emulsified by adding the solution in the part D. The mixture was cooled, and part B was added thereto at about 50℃and dissolved by stirring.

Example 67 skin Care cream

/>

(preparation method)

Part a was heated to about 70 ℃ to dissolve. And uniformly dissolving the part B. Part C was heated to about 70℃to disperse it. While stirring with a homomixer at about 70 ℃, part A was gradually added to part C to emulsify the mixture, and after cooling to about 40 ℃, part B was added to uniformly mix the mixture.

Example 68 hand cream

/>

(preparation method)

The parts B and C were heated to about 80℃to dissolve the same. The part A was weighed into a separate vessel, heated to 100 to 120℃and gelled transparently, cooled to 80 ℃. Part B was added to part A with stirring, and part C was further added to emulsify the mixture. After mixing well, cool to about 40 ℃.

Example 69 cleansing gel

(preparation method)

Part a was heated to about 80 ℃ to dissolve. Part B was warmed to about 80 ℃. Part B was added slowly to part a with stirring, mixed and cooled to 40 ℃.

Example 70 facial cleanser

/>

(preparation method)

Example 71 shower gel

/>

(preparation method)

The whole ingredients are heated at about 80 ℃ and stirred and mixed uniformly.

Example 72 silicon-free shampoo

/>

(preparation method)

Example 73 leave-in hair Care

/>

(preparation method)

Part C was dispersed uniformly and warmed to about 80 ℃. Next, part a was heated to about 80 ℃ to be dissolved. Part A was added to part C with stirring, and after mixing well, it was cooled to about 40 ℃. Then, the portions B were added and mixed uniformly.

Example 74 shampoo for scalp

/>

(preparation method)

Part B was heated to about 80 ℃ to dissolve. The part A was weighed into a separate container, and heated to dissolve it. Part B was gradually added to part A, and the mixture was mixed uniformly, and part C was added at about 60 ℃.

Example 75 shampoo

/>

(preparation method)

The part A was mixed well at about 80 ℃. The separately weighed part B was heated to about 60 ℃ and mixed well. Part B was added slowly while stirring part A, and after mixing well, it was cooled to about 50 ℃. Further adding part C and mixing uniformly.

EXAMPLE 76 lipstick

/>

(preparation method)

Heating and melting all the components, and mixing uniformly.

Example 77 foundation

/>

(preparation method)

Stirring all the components at high speed, and mixing uniformly.

EXAMPLE 78 solid powdered foundation

(preparation method)

Mixing part A by heating. The part B was weighed in a separate container and mixed and dispersed. And adding the part A into the part B, and uniformly mixing.

Example 79 liquid foundation

(preparation method)

The part A is heated and dissolved, and the part B is heated and uniformly mixed and dispersed in the part A (part D). The C part was heated and dissolved, and the C part was added to the D part with stirring, emulsified, and cooled to about 40 ℃.

Example 90 Sun protection cosmetic

/>

(preparation method)

And heating and dissolving the part A to uniformly disperse the part A. To this, a substance for dissolving the B part by heating was added, and the mixture was emulsified and dispersed by using a homogenizer, and the mixture was stirred and cooled to room temperature.

Example 91 Sun protection cosmetic

/>

(preparation method)

So that the A part is uniformly dispersed. The parts B and C were dissolved by heating at about 70 ℃. After part A was gradually added to part B, part C was gradually added to emulsify the mixture. While stirring and cooling, part D was added at 45℃and stirred.

Example 92 antiperspirant

(preparation method)

Heating and melting all the components, and mixing uniformly.

Cosmetics containing the components (A) to (D) of the present invention described below were prepared. The obtained cosmetic has excellent moisture retention and penetration feeling, and can prevent fine wrinkles and rough skin, and make skin look plump and bright.

Example 93 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-cooled C part was added to form a uniform solution.

Example 94 moisturizing lotion

/>

(preparation method)

The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then dispersed using a high-pressure emulsifying machine (MIZUHO industrial high-pressure microfluidizer). After cooling, the pre-cooled C part was added to form a uniform solution.

Example 95 moisturizing lotion

/>

(preparation method)

Example 96 moisturizing lotion

(preparation method)

The parts A and B were heated to 70℃respectively, and the part A was added to the part B while stirring with a stirring blade (500 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-cooled C part was added to form a uniform solution.

Example 97 moisturizing lotion

(preparation method)

Example 98 whitening lotion

(preparation method)

Mixing part B to prepare a viscous liquid. The portions A and C were heated to 70℃respectively, and the portion A was added to the portion C with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-mixed part B was added to form a uniform solution.

Example 99 whitening toning lotion

/>

(preparation method)

Example 100 gel toner

/>

(preparation method)

The part A is heated to about 70 ℃ and is evenly mixed and dispersed. Mix part C and stir thoroughly and then warm to about 70 ℃. Mixing part B with stirring paddle to obtain mixed solution. Part C was added to part A, stirred at about 70℃using a homomixer, cooled to 40℃and the mixture of part B was added.

Example 101 whitening emulsion

/>

(preparation method)

The portions A and E were each heated to about 70℃to dissolve. Stirring part B to obtain viscous liquid. Heating part C to about 70deg.C, and mixing and dispersing. After part A was added while stirring part C with a homogeneous disperser, part E was added while stirring. The part D and the part B were added at about 50℃and dissolved by stirring.

Example 102 skin care cream

/>

(preparation method)

Mixing part A and part C respectively, heating to about 70deg.C, and dissolving and dispersing uniformly. Mixing part B, and stirring to obtain viscous liquid. The emulsion was obtained by adding part A to part C while stirring with a homomixer. After cooling, part B was added at about 50 ℃, stirred, and cooled to about 40 ℃.

Example 103 face washing foam

/>

(preparation method)

Example 104 shampoo for scalp

/>

(preparation method)

Part B was heated to about 80 ℃ to allow uniform dissolution. The part A was weighed into a separate container, and heated to dissolve it. Part B was gradually added to part A, and the mixture was mixed uniformly, and part C was added at about 60 ℃.

Example 105 leave-in hair conditioner

/>

(preparation method)

Part C was heated to about 80℃to dissolve it. Part a was then heated to about 80 ℃ to dissolve. Part A was added to part C with stirring, and after mixing well, the mixture was cooled to about 40 ℃. Then, add part B and mix well.

Example 106 Hair care spray

/>

(preparation method)

Example 107 Sun protection cosmetic

/>

(preparation method)

The part A is evenly mixed and dispersed. The parts B and C were each heated to about 70℃to dissolve. After part B was gradually added to part a, part C was gradually added to emulsify the mixture. While stirring and cooling, part D was added at 45℃and stirred.

In the above formulation, the details of the components described by the product names are as follows.

IS: diisostearic acid dimer dioleyl ester

Is (1) LUSPLAN PI-DA: dimer dilinoleate di (isostearyl/phytosterol)

Is (1) LUSPLAN DD-DHR: dimer dilinol hydrogenated rosin ester condensate

Is (1) LUSPLAN DD-DA 5): dimer dilinoleate

Is (1) LUSPLAN DD-DA 7): dimer dilinoleate

Is (1) LUSPLAN SR-DM 4): dimer dilinoleate, glyceryl tri (caprylic/capric) ester

R, inulin-SC: inulin

Is a NanoRepair-CMC: composition containing quaternary ammonium salt-18, quaternary ammonium salt-33, cholesterol, ceramide 2, ceramide 3, ceramide 6II and PG

Neosolue-Aqulio: bis-diethoxydiglycol cyclohexane dicarboxylic acid ester

neoglue-Aqua: (eicosanedioic acid/tetradecanedioic acid) polyglycerol-10, glycerol

neocorrect-AquaS: (eicosanedioic acid/tetradecanedioic acid) polyglycerol-10, glycerol

Neosol-dimm: malic acid diisostearate

neosol-MP: methyl amyl dipivalate

Neosolue-DE: diethylpentanediol dipentamate

Plandol-H: dimerized dilinoleate (phytosterol/isostearyl/cetyl/stearyl/behenyl)

Plandol-S: dimerized dilinoleate (phytosterol/isostearyl/cetyl/stearyl/behenyl)

Plandol-G: dimer dilinoleate bis (behenyl/isostearyl/phytosterol)

Plandol-DP: didiglycerol polyacyl adipate-2

Plandol-ISS: isostearic acid plant sterol ester

Plandol-SUN: sunflower seed oil fatty acid phytosterol ester

(Plandol-MAS): queen oil fatty acid plant sterol ester

plandol-LG 1: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester

plandol-LG 2: lauroyl glutamic acid di (phytosterol/octyldodecyl) ester

plandol-LG 3: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester

plandol-LG 4: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester

Phytocompo-PP: hydrogenated lecithin and phytosterol

Phytocompo-C: hydrogenated lecithin, phytosterol, ceramide 2, ceramide 3, ceramide 6II

And (5) Phytopresome Asta: hydrogenated lecithin, phytosterol and astaxanthin

Phytopresome Lipo-Q: hydrogenated lecithin, phytosterol, lipoic acid and coenzyme Q10

Phytopresome Cera23: hydrogenated lecithin, phytosterol, ceramide 2, ceramide 3

Is a phytochrome MEL: glycolipid, hydrogenated lecithin, BG, purified water

Tremoist-TP: tremella polysaccharide

Tremoist-SL: tremella polysaccharide aqueous solution (1%)

And (b) LP70H: hydrogenated lysolecithin

Is shown in (1) Erucalactone MCT: gamma-docosactone, tri (caprylic/capric) glyceride

Is (1) Erucalactone DES): gamma docosaacttone, diethyl sebacate

Claims

1. A composite, characterized in that:

which is used for preparing an emulsified or solubilized composition obtained by removing an organic solvent from a dispersion or solution in which the following components A1 to A3 are uniformly dispersed or dissolved in an organic solvent, and simultaneously precipitating the components A1 to A3,

a1: phosphatidylinositol,

A2: lecithin with phosphatidylcholine content of 50-99 wt%,

A3: sterols are used as the starting material for the composition,

the total content of the components A1 and A2 in the compound is 70 to 99 wt%,

the content of the component A3 is 1 to 30% by weight, and,

the weight ratio of the components A1 to A2 is 5: 95-30: 70.

2. the composite of claim 1, wherein:

the component A1 is a composition containing 40 to 75% by weight of phosphatidylinositol, which is obtained by a method comprising the following steps (1) to (3) in this order,

(1): a step of allowing a phosphatidylinositol-free phospholipase B having a substrate specificity to act on lecithin;

(2): extracting phosphatidylinositol with an organic solvent;

3. The composite of claim 1 or 2, wherein:

the component A2 is a mixture of hydrogenated lecithin and non-hydrogenated lecithin.

4. The composite of claim 1 or 2, wherein:

also contains antioxidant substances as component A4,

the complex is used for preparing an emulsified or solubilized composition, which is obtained by removing an organic solvent from a dispersion or solution in which the components A1 to A4 are uniformly dispersed or dissolved in the organic solvent, and precipitating the components A1 to A4 at the same time,

The total content of the components A1 and A2 in the composite is 70 to 97 wt%, the content of the component A3 is 2 to 20 wt%, the content of the component A4 is 1 to 10 wt%, and the weight ratio of the components A1 and A2 is 5: 95-30: 70.

5. a cosmetic product characterized by:

a complex according to any one of claims 1 to 4.

6. An external preparation for skin, characterized in that:

a complex according to any one of claims 1 to 4.